Granted Patent
B2
US 12,503,479 · App. 17/044,757 · Granted Dec 23, 2025
Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
Assignee:
CELLECTAR BIOSCIENCES, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are phospholipid ether (PLE) molecules. Further provided are phospholipid-flavagline conjugates. The phospholipid-flavagline conjugate may include a PLE conjugated to a flavagline via a linker. Further provided herein are methods of treating cancer in a subject and methods of targeting a drug to a tumor or cancer cell in a subject.
Claims (16)
1 . A conjugate according to Formula II, or a salt thereof:
wherein X is,
or methylene, or bond;
Y is a linker comprising a disulfide; and
Z is a flavagline anti-cancer drug.
2 . The conjugate of claim 1 , wherein the flavagline anti-cancer drug comprises FLV-1, FLV-3, a derivative or analog thereof, or a combination thereof.
3 . The conjugate of claim 1 , wherein the linker comprises the following:
4 . The conjugate of claim 1 , selected from the following:
5 . A composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.
6 . A method of treating cancer in a subject, the method comprising administering to the subject the conjugate of claim 1 .
7 . A method of targeting a drug to a tumor or cancer cell in a subject, the method comprising administering to the subject the conjugate of claim 1 .
8 . The method of claim 6 , wherein the flavagline anti-cancer drug localizes or travels to the cytoplasm or organelle of the tumor or cancer cell.
9 . The method of claim 6 , wherein the conjugate or flavagline anti-cancer drug is selective for cancer cells in the subject.
10 . The method of claim 6 , wherein the conjugate or flavagline anti-cancer drug is incorporated into at least about 2-fold more tumor or cancer cells than healthy cells.
11 . The method of claim 6 , wherein the cancer is selected from melanoma, brain cancer, lung cancer, adrenal cancer, liver cancer, renal or kidney cancer, pancreatic cancer, esophageal cancer, gastric cancer, stomach cancer, colon cancer, colorectal cancer, anal cancer, prostate cancer, ovarian cancer, breast cancer, cervical cancer, lymphoma, leukemia, myeloma, hematologic cancer, hepatocarcinoma, retinoblastoma, glioma, sarcoma, blastoma, squamous cell carcinoma, and adenocarcinoma.
12 . The method of claim 6 , wherein the subject is human.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 2, 2021
From: LONGCOR, JARROD
To: CELLECTAR BIOSCIENCES, INC.
Reel/Frame 055112/0449 →
Continuity (2)
Provisional Application
62655659
· Apr 10, 2018
References Cited (157)
US 4938949A
· Borch et al.
· 1990
[cited by applicant]
US 4965391A
· Counsell et al.
· 1990
[cited by applicant]
US 5411947A
· Hostetler et al.
· 1995
[cited by applicant]
US 5580859A
· Felgner et al.
· 1996
[cited by applicant]
US 5679647A
· Carson et al.
· 1997
[cited by applicant]
US 7632644B2
· Weichert et al.
· 2009
[cited by applicant]
US 7700075B2
· Weichert et al.
· 2010
[cited by applicant]
US 7811548B1
· Pinchuk et al.
· 2010
[cited by applicant]
US 7893286B2
· Pinchuk et al.
· 2011
[cited by applicant]
US 8022235B2
· Pinchuk
· 2011
[cited by examiner]
US 8486924B2
· Ansell et al.
· 2013
[cited by applicant]
US 8535641B2
· Weichert et al.
· 2013
[cited by applicant]
US 8540968B2
· Weichert et al.
· 2013
[cited by applicant]
US 8871181B2
· Pinchuk et al.
· 2014
[cited by applicant]
US 8877159B2
· Weichert et al.
· 2014
[cited by applicant]
US 8877160B2
· Weichert et al.
· 2014
[cited by applicant]
US 9345718B1
· Weichert
· 2016
[cited by applicant]
US 9480754B2
· Weichert
· 2016
[cited by applicant]
US 9925269B2
· Weichert et al.
· 2018
[cited by applicant]
US 20020197306A1
· McDonald et al.
· 2002
[cited by applicant]
US 20070167408A1
· Perrissoud et al.
· 2007
[cited by applicant]
US 20100120727A1
· Xu
· 2010
[cited by applicant]
US 20100286510A1
· Pinchuk et al.
· 2010
[cited by applicant]
US 20110064661A1
· Pinchuk et al.
· 2011
[cited by applicant]
US 20120156133A1
· Pinchuk et al.
· 2012
[cited by applicant]
US 20140255432A1
· Baiocchi et al.
· 2014
[cited by applicant]
US 20230066517A1
· Longcor
· 2023
[cited by examiner]
DE 4408011C1
· 1995
[cited by applicant]
JP H06263643A
· 1994
[cited by applicant]
JP 2004043513A
· 2004
[cited by applicant]
JP 2008545614A
· 2008
[cited by applicant]
JP 2011504937A
· 2011
[cited by applicant]
JP 2013504590A
· 2013
[cited by applicant]
WO 1998024480A1
· 1998
[cited by applicant]
WO 2007013894A2
· 2007
[cited by applicant]
WO 2010132428A1
· 2010
[cited by applicant]
WO 2010144788A2
· 2010
[cited by applicant]
WO 2011031919A2
· 2011
[cited by applicant]
WO 2014106826A2
· 2014
[cited by applicant]
WO 2016036794A1
· 2016
[cited by applicant]
WO 2017201528A1
· 2017
[cited by applicant]
WO 2018205008A1
· 2018
[cited by applicant]
WO 2019065774A1
· 2019
[cited by applicant]
WO 2019157138A1
· 2019
[cited by applicant]
WO 2019203191A1
· 2019
[cited by applicant]
WO 2021072300A1
· 2021
[cited by applicant]
Alam, M., et al. “Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents.” Archives of pharmacal research 41 (2018): 35-45.
[cited by applicant]
Masuda, S. et al. A trimethyllysine-containing trityl tag for solubilizing hydrophobic peptides. Org. Biomol. Chem., 2019, 17, 10228-10236.
[cited by applicant]
Chinese Patent Office Notification of the First Office Action for Application No. 202080074561.3, dated Aug. 17, 2023, 17 pages with translation.
[cited by applicant]
European Patent Office Extended Search Report for Application No. 20862948.5 dated Sep. 13, 2023 (9 pages).
[cited by applicant]
Turkish Patent Office Action for Application No. 2020/16160, dated Aug. 3, 2023 (5 pages with translation).
[cited by applicant]
Arpicco et al., “Preparation and characterization of novel poly(ethylene glycol) paclitaxel derivatives”, Int J Pharm, Oct. 1, 2013, vol. 454, No. 2, pp. 653-659 (Epub May 20, 2013).
[cited by applicant]
Bao et al., “Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor”, Cancer Res, Aug. 15, 2006, vol. 66, No. 16, pp. 7843-7848.
[cited by applicant]
Bellina et al., “Novel imidazole-based combretastatin A-4 analogues: Evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin”, Bioorganic & Medicin…
[cited by applicant]
Blitterswijk et al., “Anticancer mechanisms and clinical application of alkylphospholipids”, Biochimica et Biophysica Acta, vol. 1831, 2013, pp. 663-674.
[cited by applicant]
Brown et al., “Lipid Raft Localization of ErbB2 in Vestibular Schwannoma and Schwann Cells,” Otology & Neurology, 2007, vol. 29, pp. 79-85.
[cited by applicant]
Buchwald, et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis”, Surgery, Oct. 1980, vol. 88, No. 4, pp. 507-516.
[cited by applicant]
Cohen et al., “Intracranial C6 glioma model in adult Wistar-Furth rats”, J Neurooncol, Feb. 1990, vol. 8, No. 1, pp. 95-96.
[cited by applicant]
de Mendoza et al., “Lipid Nanomedicines of Anticancer drug Therapy,” Journal of Biomedical Nanotechnology, 2009, 5: 323-343.
[cited by applicant]
Donnelley et al., “DNA Vaccines”, Annu. Rev. Immunol., vol. 15, 1997, pp. 617-648.
[cited by applicant]
Fleshner et al., “Prostate Cancer Prevention”, American Cancer Society, 2007, pp. 1889-1899.
[cited by applicant]
Goldmacher et al., “Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells”, Ther Deliv, Mar. 2011, 2(3), 397-416.
[cited by applicant]
Guo et al., “Lipid metabolism emerges as a promising target for malignant glioma therapy,” CNS Oncol., 2013, 2(3):289-299.
[cited by applicant]
Heagerty et al., “Time-Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker”, Biometrics, vol. 56, 2000, pp. 337-344.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2019/26853 dated Oct. 13, 2020 (6 pages).
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US19/26853 dated Aug. 16, 2019 (14 pages).
[cited by applicant]
Kilkus et al., “Ceramide in Rafts (Detergent-Insoluble Fraction) Medicates Cell Death in Neurotumor Cell Lines,” Journal of Neuroscience Research, 2003, 72:65-75.
[cited by applicant]
Kumar et al., “PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis”, Biomed Rest Int., 2015, 705-745.
[cited by applicant]
Langer, “New methods of drug delivery”, Science, Sep. 28, 1990, vol. 249, No. 4976, pp. 1527-1533.
[cited by applicant]
Lerner et al., “The synthesis of beta.-keto lactones via cyclization beta-keto ester dianions or the cyclization of Meldrum's acid derivatives”, Can J Chem, 1992, vol. 70, No. 5, pp. 1427-1445.
[cited by applicant]
Li et al., “Elevated Levels of Cholesterol-Rich Lipid Rafts in Cancer Cells Are Correlated with Apoptosis Sensitivity Induced by Cholesterol-Depleting Agents,” American Journal of Pathology, 2006, vol. 168, No. 4, pp. 1…
[cited by applicant]
Mahato et al., “Prodrugs for improving tumor targetability and efficiency,” Advanced Drug Delivery Reviews, 2011, vol. 63, pp. 659-670.
[cited by applicant]
Mollinedo et al., “Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy,” Journal of Lipid Research, May 2020, vol. 61, No. 5, pp. 611-635.
[cited by applicant]
Murai, “The Role of Lipid Rafts in Cancer Cell Adhesion and Migration,” International Journal of Cell Biology, 2012, Article ID 763283, 6 pages.
[cited by applicant]
National Center for Biotechnology Information. PubChem Substance Record for SID 252827261, SID 252827261, Source: Thomson Pharma. <https://pubchem.ncbi.nlm.nih.gov/substance/252827261> Available Oct. 2015.
[cited by applicant]
Pedersen et al., “Synthesis and Biophysical Characterization of Chlorambucil Anticancer Ether Lipid Prodrugs”, J. Med. Chem., vol. 52, 2009, pp. 3408-3415.
[cited by applicant]
Peters et al., “Antibody-drug conjugates as novel anti-cancer chemotherapeutics”, Bioscience Reports, 2015, vol. 35, No. 4, e00225, 20 pages.
[cited by applicant]
Peters et al., “Probing cell-division phenotype space and Polo-like kinase function using small molecules”, Nat Chem Biol, vol. 2, No. 11, 2006, pp. 618-626.
[cited by applicant]
Pinchuk et al., “Synthesis and Structure-Activity Relationship Effects on the Tumor Avidity of Radioiodinated Phospholipid Ether Analogues”, J. Med. Chem., vol. 49, pp. 2155-2165.
[cited by applicant]
Poste et al., “Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells”, Methods in Cell Biology (Edited by Prescott, vol. XIV) Chapter 4, 1976, pp. 34-68.
[cited by applicant]
Prichard et al., “The prevention of breast cancer,” British Journal of Surgery, 2003, 90, pp. 772-783.
[cited by applicant]
PubChem SID 104583910, Feb. 22, 2011 (7 pages).
[cited by applicant]
Rampy et al., “Synthesis and Biological Evaluation of Radioiodinated Phospholipid Ether Analogs,” Nuclear Medicine and Biology, 1995, 22, pp. 505-512.
[cited by applicant]
Rodriguez-Antona, “Pharmacogenomics of paclitaxel”, Pharmacogenomics, vol. 11, No. 6, 2010, pp. 621-623.
[cited by applicant]
Sathornsumetee et al., “Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma”, Neuro Oncol, Dec. 2010, 12(12), pp. 1300-1310.
[cited by applicant]
Saudek et al., “A preliminary trial of the programmable implantable medication system for insulin delivery”, N Engl J Med, Aug. 31, 1989, 321(9), pp. 574-579.
[cited by applicant]
Sefton, “Implantable pumps”, Crit Rev Biomed Eng, 1987, 14(3), pp. 201-240.
[cited by applicant]
Snyder et al., “Alkyl and alk-1-enyl ethers of glycerol in lipids from normal and neoplastic human tissues”, Cancer Res, Jan. 1969, 29(1), pp. 251-257.
[cited by applicant]
Snyder et al., “The occurrence and metabolism of alkyl and alk-1-enyl ethers of glycerol in transplantable rat and mouse tumors”, Cancer Res, May 1968, 28(5), pp. 972-978.
[cited by applicant]
Subczynski et al., “Dynamics of raft molecules in the cell and artificial membranes: approaches by pulse EPR spin labeling and single molecule optical microscopy,” Biochimica et Biophysica Acta, 2003, 1610:231-243.
[cited by applicant]
Tranoy-Opalinski et al., “beta-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update”, Eur J Med Chem, 2014, vol. 74, pp. 302-313.
[cited by applicant]
Tranoy-Opalinski et al., “Design of self-immolative linkers for tumour-activated prodrug therapy”, Anticancer Agents Med Chem, Aug. 2008, vol. 8, No. 6, pp. 618-637.
[cited by applicant]
Wang et al., “Doxorubicin conjugated phospholipid preodrugs as smart nanomedicine plataforms for cancer therapy,” Journal of Materials Chemistry, 2015, 3, pp. 3297-3305.
[cited by applicant]
Wang, “Anti-Paclitaxel Resistance Effect of Somatostatin Receptors Mediated Targeted Therapy on Non-Small Cell Lung Cancer Cells and its Possible Mechanisms,” Doctoral Dissertation of Shandong University, Jun. 29, 2010,…
[cited by applicant]
Weichert et al., Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy, Sci Transl Med, Jun. 11, 2014, vol. 6, No. 240, pp. 240ra75.
[cited by applicant]
Weichert et al., Radioiodination via isotope exchange in pivalic acid, Int J Appl Rad Isotopes, 1986, vol. 37, No. 8, pp. 907-913.
[cited by applicant]
Eurasian Patent Office Action for Application No. 202092369 dated Aug. 2, 2022 (7 pages with translation).
[cited by applicant]
Eurasian Patent Office Action for Application No. 202290818 dated Oct. 9, 2023 (8 pages with English translation).
[cited by applicant]
United Arab Emirates Office Action for Application No. P6001410/ 2020, dated Dec. 20, 2023 (9 pages).
[cited by applicant]
Vietnamese Patent Office Action for Application No. 1-2020-06001, dated Dec. 27, 2023 (4 pages with translation).
[cited by applicant]
European Patent Office Extended Search Report for Application No. 20875069.5 dated Nov. 16, 2023 (7 pages).
[cited by applicant]
Eurasian Patent Office action for Application No. 202092369 dated Nov. 30, 2021 (4 pages with English translation).
[cited by applicant]
European Patent Office Extended Search Report for Application No. 19784548.0 dated Mar. 14, 2022 (18 pages).
[cited by applicant]
North et al., “Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs”, Bioorganic & Medicinal Chemistry, 2009, vol. 17, No. 9, pp. 3433-3442.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2020050459 dated Mar. 24, 2022 (6 pages).
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US20/055121 dated Apr. 12, 2022 (5 pages).
[cited by applicant]
Australian Patent Office Action for Application No. 2019251483 dated Apr. 19, 2021 (3 pages).
[cited by applicant]
Japanese Patent Office Action for application 2020-555450, dated Mar. 14, 2023, (8 pages with translation).
[cited by applicant]
Mexican Patent Office Action for application MX/A/2020/010741, dated Mar. 3, 2023 (8 pages with machine translation).
[cited by applicant]
Israeli Patent Office Action for application 277875, dated Mar. 12, 2023 (5 pages).
[cited by applicant]
Israeli Patent Office Action for application 304245, dated Jan. 7, 2024 (5 pages).
[cited by applicant]
Korean Patent Office Action for application 10-2020-7030504, dated Feb. 12, 2024 (15 pages with translation).
[cited by applicant]
Canadian Patent Office—Office Action for Application No. 3,095,515 dated Mar. 27, 2023 (7 pages).
[cited by applicant]
Basmadjian, C., et al. “Flavaglines: potent anticancer drugs that target prohibitins and the helicase elF4A.” Future medicinal chemistry 5.18 (2013): 2185-2197.
[cited by applicant]
U.S. National Library of Medicine, “Sarcoma MeSH Descriptor Data”, <https://meshb.nlm.nih.gov/record/ui?ui=D012509>, accessed May 29, 2021 (1 page).
[cited by applicant]
Dickey, “Medscape Fibrosarcoma—Overview”, <https://emedicine.medscape.com/article/1257520-overview>, accessed May 29, 2021 (1 page).
[cited by applicant]
Indian Intellectual Property First Examination Report for application 202017042352, dated Apr. 29, 2022 (7 pages).
[cited by applicant]
Eurasian Patent Office Action for Application No. 202290942 dated Nov. 3, 2022 (12 pages with translation).
[cited by applicant]
Chinese Patent Office Action for Application No. 201980036064.8 dated Jan. 5, 2023 (19 pages with translation).
[cited by applicant]
Eurasian Patent Second Office Action for Application No. 202290942 dated Jun. 1, 2023 (13 pages, English translation included).
[cited by applicant]
European Patent Office Partial Supplementary Search Report for Application No. 19784548.0 dated Dec. 8, 2021 (20 pages).
[cited by applicant]
Thuaud et al., “Synthetic Analogue of Rocaglaol Displays a Potent and Selective Cytotoxicity in Cancer Cells: Involvement of Apoptosis Inducing Factor and Caspase-12”, Journal of Medicinal Chemistry, 2009, vol. 52, No. …
[cited by applicant]
Canadian Patent Office First Office Action for Application No. 2,968,145 dated Nov. 15, 2021 (6 pages).
[cited by applicant]
Singaporean Patent Office Written Opinion for Application No. 11202203580P, dated Apr. 1, 2024 (8 pages).
[cited by applicant]
Singaporean Patent Office Written Opinion for Application No. 11202202467P, dated Apr. 1, 2024 (9 pages).
[cited by applicant]
Chinese Patent Office Action Notification of the First Office Action for Application No. 202080081971.7, dated Apr. 22, 2024 (22 pages with translation).
[cited by applicant]
New Zealand Patent Office Patent Examination Report 1 for Application No. 768472, dated May 29, 2024 (5 pages).
[cited by applicant]
Zihan, G. et al., Overview of the development of tumor molecular targeted therapeutic drugs. Shanghai Medicine, 2018, Issue 05, 9-13 (English abstract, 3 pages).
[cited by applicant]
Wenqi, L. et al., Study on the dynamic activity of tegafur derivatives with lecithin analogs as carriers, Journal of Hunan University (Natural Science Edition), vol. 31, No. 02, 10-12, 2004 (English Abstract, 4 pages).
[cited by applicant]
Grudzinski, J., et al. “CLR 125 Auger electrons for the targeted radiotherapy of triple-negative breast cancer.” Cancer Biotherapy & Radiopharmaceuticals 33.3 (2018): 87-95.
[cited by applicant]
Mexican Patent Office Action for application MX/A/2022/003044, dated Feb. 6, 2025 (10 pages with machine translation).
[cited by applicant]
Japanese Patent Office Action for application 2020-516159, dated Aug. 13, 2024, (7 pages with translation).
[cited by applicant]
Indian Intellectual Property Examination Report for application 202217015147, dated Sep. 10, 2024 (7 pages).
[cited by applicant]
Japanese Patent Office Decision of Final Rejection for application 2020-516159, dated Mar. 4, 2025, (5 pages with translation).
[cited by applicant]
Wikipedia. Flavaglines. Version dated Feb. 4, 2012. Available online at https://web.archive.org/ web/20120204162050/https://en.wikipedia.org/wiki/Flavagline (1 page).
[cited by applicant]
Eurasian Patent Office. Office Action for Application No. 202290818, dated May 5, 2025 (6 pages with translation).
[cited by applicant]
Chinese Patent Office. Office Action for Application No. 202310088164.3, dated May 16, 2025 (18 pages with machine translation).
[cited by applicant]
D'Abronzo et al., “elF4E Phosphorylation in Prostate Cancer”, Neoplasia, vol. 20, No. 6, 2018, pp. 563-573.
[cited by applicant]
Mabe et al., “Asymmetric radical addition of TEMPO to titanium enolates”, Org Lett, Jan. 17, 2014, 16(2), 516-9, Epub Dec. 31, 2013.
[cited by applicant]
Saudi Authority for Intellectual Property First Examination Report for application 520420298, dated May 17, 2022 (5 pages with Statement of Relevance).
[cited by applicant]
Chinese Patent Office Action for Application No. 201580073699.7 dated May 5, 2022 (10 pages with Statement of Relevance).
[cited by applicant]
Ignatov, M.E. et al., “Conjugate as Subject Matter”, Patent Attorney (Russ.), 2019, No. 4, pp. 35-46, http://www.eapo.org/pdf/home/publications/2019ignatov_lubyako_serova.pdf.
[cited by applicant]
Mexican Patent Office. Office Action for Application No. MX/a/2022/003044, dated Jul. 10, 2025, 12 pages with machine translation.
[cited by applicant]
Australian Patent Office. Office Action for Application No. 2020346898 dated Aug. 12, 2025 (4 pages).
[cited by applicant]
Canadian Patent Office. Office Action for Application No. 3,150,991, dated Aug. 18, 2025 (5 pages).
[cited by applicant]